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Resveratrol is a polyphenolic compound found in several plants. In the last decades, the interest in this compound
has enormously increased after benefits on metabolism and increased lifespan of various organisms have been
reported with its supplementation. Several in-vitro and animal studies have observed that resveratrol can act on
multiple molecular targets, including sirtuins, a class of NAD + −dependent deacetylases. Despite the enthusiastic
results reported in many animal- and in-vitro studies, few trials have been performed in humans with contrasting
results. These conflicting data may be due at least in part to differences in the characteristics of the patients
enrolled, the dosages and the duration of supplementation. Furthermore, many questions remain still unsolved,
such as the dose or the duration of treatment to maximize its effects, the bioavailability of resveratrol and the role
of food matrix to improve its bioactivity.
In conclusion, at present the use of resveratrol as a supplement is not yet justified by the existing evidence.
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The phytoalexin resveratrol (3,5,4’-trihydroxystilbene), a
non-flavonoids polyphenolic compound found in many
plants such as grapes, and in red wine was first disco-
vered in 1940 [1,2].
Resveratrol owes its fame to the so-called “French
Paradox”. In the early 90s, the term derived from the ob-
servation that the French adults showed a relatively low
incidence of coronary heart disease in comparison to
the corresponding-age individuals from other Western
countries, despite a high dietary intake of saturated fatty
acids. The French scientist Renaud attributed this para-
dox to the increased consumption of red wine [3] and,
later, the high resveratrol content of wine has been iden-
tified as one of the potential mechanisms of the benefits
of red wine [4]. From that moment, the interest in this
natural compound has grown enormously. Research has
thereafter shifted from human to animal models and the
number of studies on resveratrol has increased extra-
ordinarily since 1997, when its anti-cancer properties
have been reported [4]. Several authors have investigated
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A long list of beneficial effects and many possible direct
or indirect molecular targets and mechanisms of action
of resveratrol have been described in animal and in vitro
studies. Only recently, research has focused on humans
again, and so far a number of human clinical trial have
been conducted.Main text
A milestone in resveratrol research came in the early
2000s when some authors reported that resveratrol is able
to mimic caloric restriction effects and increased yeast,
worms, flies and rodents lifespan [5,6]. This effect was
ascribed to the resveratrol ability to activate sirtuin pro-
teins, NAD +-dependent de-acetylase involved in the regu-
lation of metabolism, apoptosis, mitochondrial biogenesis,
inflammation, fatty acid metabolism, and glucose ho-
meostasis [7-10]. But sirtuins are not the only target of
resveratrol and thanks to its ability to act on numerous
molecular targets, resveratrol exhibits versatile biological
effects: from the inhibition of angiogenesis, cancer cell and
metastatic cell growth [11-24] to the improvement of vas-
cular function, arterial blood pressure values, and platelet
aggregation [25-27], and the anti-inflammatory [28,29],
antioxidant [30,31] and hypoglycaemic effects [32-38].Ltd. This is an Open Access article distributed under the terms of the Creative
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conflicting or controversial results about the anticancer,
cardioprotective and anti-inflammatory properties of
resveratrol [39-50]. Other sources of controversy derive
from the fact that many of the hypothesized mechanisms
have not yet been demonstrated in humans [27]. How-
ever, some positive results have been found. A recent
meta-analysis of 11 human clinical trials, investigating
the effects of resveratrol on the metabolic pattern of type
2 diabetic patients, points out a beneficial effect of
resveratrol consumption on fasting glucose and glyco-
sylated haemoglobin values, and insulin resistance mea-
sured by the homeostatic model assessment [51].
Why have not all the promising results found in pre-
clinical studies been confirmed in humans?
Differences in formulation, dosage of resveratrol and
duration of follow-up may at least in part justify these
conflicting results. However, many other issues remain
unresolved. For example, the dose of resveratrol to
maximize its effects without safety concerns is still un-
known; similarly the duration of supplementation remains
a matter of concern (a high dose for a short-term or a low
dose for a long period?). Moreover, the relationship bet-
ween the low bioavailability and the high bioactivity of
resveratrol, the so-called resveratrol paradox, has not yet
been solved. Since this molecule is rapidly metabolized
and its concentrations quickly disappear in the blood, it is
difficult to justify its benefits, while the knowledge of me-
tabolites or mediators responsible for the effects of res-
veratrol is still scanty [52].
The majority of trans-resveratrol metabolites were
found to be derived by glucuronidation or sulfation. Since
the rapid metabolism seems to be one of the major rea-
sons for the lower effect on humans, a part of the research
is focusing on how to improve the bioavailability of resve-
ratrol. One way to improve the bioavailability may be the
combination of resveratrol with other agents that inhibit
its metabolism in vivo. Studies have shown that natural
compounds, including quercetin and piperine (an alkaloid
derived from black pepper), can inhibit glucuronidation
and sulfation of resveratrol [53-55]. However, further stu-
dies are needed to assess whether these combinations may
determine an increase in its bioavailability.
The role of resveratrol in an “epigenetic diet”, a diet
with a potential impact in delaying ageing and preven-
ting age-related diseases, could be a further topic worthy
of investigation.
Finally, another interesting but unsolved topic is the
possible influence of the food matrix on the bioavailabil-
ity of resveratrol in humans. Some authors have shown
that trans-resveratrol is better absorbed when assumed
through wine or grape juice than from tablets [56];
in vivo bioavailability and bioactivity could be increased
by the food matrix because of the presence of othernatural compounds, such as other polyphenols that seem
to play a synergic role and increase resveratrol bio-
activity [57].
Conclusions
The versatile properties of resveratrol found in in-vitro
and animal studies have not been unequivocally confirmed
in human studies. At present, resveratrol should be as-
sumed by natural foods, mainly through the moderate
consumption of red wine, grape juice or peanuts, while
the consumption as a supplement is not justify by the
existing scientific literature. Many issues remain certainly
open, and a resveratrol formulation with increased bio-
availability and effective in humans as in mice has yet to
be discovered.
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